INSILICO MEDICINE

InSilico Medicine Cayman TopCo

英矽智能

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 3696)

VOLUNTARY ANNOUNCEMENT
INSILICO MEDICINE COMPLETES FIRST-IN-HUMAN DOSING IN PHASE I CLINICAL STUDY OF AI-DRIVEN NLRP3 INHIBITOR ISM8969, ACHIEVING FIRST CLINICAL MILESTONE IN COLLABORATION WITH HYGTIA THERAPEUTICS

This announcement is made by InSilico Medicine Cayman TopCo (the "**Company**", together with its subsidiaries, the "**Group**" or "**Insilico Medicine**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business updates of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that, the Company has achieved the first clinical milestone in its co-development collaboration with Hygtia Therapeutics Co., Ltd ("**Hygtia Therapeutics**") with the completion of first-in-human dosing in the Phase I study of ISM8969.

As the first study in the clinical development of ISM8969, this single-center, Phase I, randomized, double-blind, placebo-controlled trial, including both single ascending dose (SAD) and multiple ascending dose (MAD) cohorts, will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered ISM8969 in healthy participants and in obese adult participants at risk of cardiovascular disease. The Phase I study is conducted in Australia and is expected to enroll 80 healthy participants as well as 20 obese adult participants at risk of cardiovascular disease.

ISM8969 is a potentially best-in-class, orally available, brain-penetrant small-molecule inhibitor of the NLRP3 inflammasome being developed to treat chronic neuroinflammation and central nervous system (CNS) disorders, including Parkinson's disease. To accelerate the global development of this candidate, Insilico Medicine has entered into an exclusive global strategic co-development collaboration with Hygtia Therapeutics, an incubatee of Shenzhen Pengfu Biopharmaceutical Industry Private Equity Investment Fund Partnership Enterprise (Limited Partnership) and Fosun Pharma. Under the relevant agreement, Insilico Medicine grants Hygtia Therapeutics worldwide rights to research, develop, register, manufacture, and commercialize ISM8969, with each party holding 50% of the global rights and interests to the program. In return, Insilico Medicine is eligible to receive upfront and milestone payments totaling up to USD66 million.

Forward Looking Statement

There is no assurance that any forward-looking statements regarding the business development of the Group in this announcement or any of the matters set out herein are attainable, will actually occur or will be realized or are complete or accurate. The financial and other data relating to the Group as disclosed in this announcement has also not been audited or reviewed by its auditors. Shareholders and/or potential investors of the Company are advised to exercise caution when dealing in the shares of the Company and not to place any excessive reliance on the information disclosed herein. Any shareholder or potential investor who is in doubt is advised to seek advice from professional advisors.

By order of the Board
InSilico Medicine Cayman TopCo
Mr. Aleksandrs Zavoronkovs, Ph.D.
Chairman, Executive Director, CEO and CBO

Hong Kong, June 17, 2026

As at the date of this announcement, the board of directors of the Company comprises Mr. Aleksandrs Zavoronkovs, Ph.D. and Mr. Feng Ren, Ph.D. as executive directors; Mr. Kan Chen, Ph.D., Mr. Chuen Yan Leung, Ph.D., and Mr. Long Shi as non-executive directors; and Mr. Jingsong Wang, Ph.D., Ms. Denitsa Milanova, Ph.D. and Mr. Roman Kyrychynskyi as independent non-executive directors.